Web-based references relating to the number under the disk sign, listed by page header
Limb ischaemia
131 Thrombangiitis obliterans (Buerger's disease): still a limb
threatening disease. Author: Van Damme H, De Leval L, Creemers E, Limet R.
Journal: Acta Chir Belg; 1997 Oct ; 97(5):229-36. PubMed ID: 9394964.
[Link]
596
132 Gadolinium-enhanced MR angiography as first-line preoperative
imaging in high-risk patients with lower limb ischemia. Author: Brillet PY,
Vayssairat M, Tassart M, Deux JF, Bazot M, Allaire E, Boudghene F. Journal: J
Vasc Interv Radiol; 2003 Sep ; 14(9 Pt 1):1139-45. PubMed ID: 14514805.
[Link]
596
133 Exercise training versus angioplasty for stable claudication.
Long and medium term results of a prospective, randomised trial.
[Link]
596
134 Does supervised exercise offer adjuvant benefit over exercise
advice alone for the treatment of intermittent claudication? A randomised trial.
Author: Cheetham DR, Burgess L, Ellis M, Williams A, Greenhalgh RM, Davies AH.
Journal: Eur J Vasc Endovasc Surg; 2004 Jan ; 27(1):17-23. PubMed ID: 14652832.
[Link]
596
135 Vein versus polytetrafluoroethylene in above-knee femoropopliteal
bypass grafting: five-year results of a randomized controlled trial. Author:
Klinkert P, Schepers A, Burger DH, van Bockel JH, Breslau PJ. Journal: J Vasc
Surg; 2003 Jan ; 37(1):149-55. PubMed ID: 12514593.
[Link]
596
136 Warfarin improves the outcome of infrainguinal vein bypass
grafting at high risk for failure. Author: Sarac TP, Huber TS, Back MR, Ozaki
CK, Carlton LM, Flynn TC, Seeger JM. Journal: J Vasc Surg; 1998 Sep ;
28(3):446-57. PubMed ID: 9737454.
[Link]
596
137 Major lower extremity amputation: outcome of a modern series.
Author: Aulivola B, Hile CN, Hamdan AD, Sheahan MG, Veraldi JR, Skillman JJ,
Campbell DR, Scovell SD, LoGerfo FW, Pomposelli FB. Journal: Arch Surg; 2004 Apr
; 139(4):395-9; discussion 399. PubMed ID: 15078707.
[Link]
596
138 Gabapentin in postamputation phantom limb pain: a randomized,
double-blind, placebo-controlled, cross-over study. Author: Bone M, Critchley P,
Buggy DJ. Journal: Reg Anesth Pain Med; 2002 Sep-Oct ; 27(5):481-6. PubMed ID:
12373695.
[Link]
596
139 Surgery versus thrombolysis for acute limb ischaemia: initial
management.
[Link]
597
Obstruction of the bowel
140 For an exposition on Ogilvie's syndrome see the reference below.
[Link]
599
141 Chronic Intestinal Pseudo-Obstruction. Journal: Curr Treat
Options Gastroenterol; 2005 Feb ; 8(1):3-11. PubMed ID: 15625029.
[Link]
599
Some paediatric surgical emergencies
142 An idea suggested by Dr. P.S. Ireland, reflecting on current
dietary habit after a consultation with a patient with intussusception
[Link]
600
Torsion of the testis
No links
Urinary retention and benign prostatic hypertrophy
143 Tamsulosin in the management of patients in acute urinary
retention from benign prostatic hyperplasia. Author: Lucas MG, Stephenson TP,
Nargund V. Journal: BJU Int; 2005 Feb ; 95(3):354-7. PubMed ID: 15679793.
[Link]
602
144 Comparison of long-term results of transurethral incision of the
prostate with transurethral resection of the prostate, in patients with benign
prostatic hypertrophy. Author: Tkocz M, Prajsner A. Journal: Neurourol Urodyn;
2002 ; 21(2):112-6. PubMed ID: 11857663.
[Link]
602
145 A randomized prospective study of laser ablation of the prostate
versus transurethral resection of the prostate in men with benign prostatic
hyperplasia. Author: Shingleton WB, Terrell F, Renfroe DL, Kolski JM, Fowler JE.
Journal: Urology; 1999 Dec ; 54(6):1017-21. PubMed ID: 10604701.
[Link]
602
146 Serenoa repens for benign prostatic hyperplasia. Author: Wilt T,
Ishani A, Mac Donald R. Journal: Cochrane Database Syst Rev; 2002 ;
(3):CD001423. PubMed ID: 12137626.
[Link]
602
147 Saw palmetto for benign prostatic hyperplasia. Author: Bent S,
Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, Avins AL. Journal: N Engl
J Med; 2006 Feb 9 ; 354(6):557-66. PubMed ID: 16467543.
[Link]
602
148 A comparison of the effect of 1.5% glycine and 5% glucose
irrigants on plasma serum physiology and the incidence of transurethral
resection syndrome during prostate resection. Author: Collins JW, Macdermott S,
Bradbrook RA, Keeley FX, Timoney AG. Journal: BJU Int; 2005 Aug ; 96(3):368-72.
PubMed ID: 16042732.
[Link]
603
(footnote) Urology. 1999 Nov;54(5):857-61. Lechevallier E, Eghazarian C, Ortega
JC, Roux F, Coulange C. Effect of digital rectal examination on serum complexed
and free prostate-specific antigen and percentage of free prostate-specific
antigen. English
[Link]
602
(footnote) [The effect of acute urinary retention on serum prostate specific
antigen concentration] Author: Hua LX, Wu HF, Sui YG, Cheng SG, Xu ZQ. Journal:
Zhonghua Nan Ke Xue; 2002 ; 8(2):134-5. PubMed ID: 12479031.
[Link]
602
(footnote) The influence of finasteride on the development of prostate cancer.
Author: Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber
MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM,
Crowley JJ, Coltman CA. Journal: N Engl J Med; 2003 Jul 17 ; 349(3):215-24.
PubMed ID: 12824459.
[Link]
602
Urinary incontinence
149 Evaluation of female pelvic-floor muscle function and strength.
Author: B" K, Sherburn M. Journal: Phys Ther; 2005 Mar ; 85(3):269-82. PubMed
ID: 15733051.
[Link]
604
150 Duloxetine vs placebo in the treatment of stress urinary
incontinence: a four-continent randomized clinical trial. Author: Millard RJ,
Moore K, Rencken R, Yalcin I, Bump RC, Duloxetine UI Study Group . Journal: BJU
Int; 2004 Feb ; 93(3):311-8. PubMed ID: 14764128.
[Link]
604
Web-based references relating to the number under the disk sign
151 Burch procedure compared with sling for stress urinary
incontinence: a decision analysis.
[Link]
604
152 Clinical efficacy and safety of tolterodine compared to placebo
in detrusor overactivity. Author: Millard R, Tuttle J, Moore K, Susset J, Clarke
B, Dwyer P, Davis BE. Journal: J Urol; 1999 May ; 161(5):1551-5. PubMed ID:
10210394.
[Link]
605
153 Tolterodine versus oxybutynin in the treatment of urge urinary
incontinence: a meta-analysis. Author: Harvey MA, Baker K, Wells GA. Journal: Am
J Obstet Gynecol; 2001 Jul ; 185(1):56-61. PubMed ID: 11483904.
[Link]
605
154 Use of peripheral neuromodulation of the S3 region for treatment
of detrusor overactivity: a urodynamic-based study. Author: Klingler HC, Pycha
A, Schmidbauer J, Marberger M. Journal: Urology; 2000 Nov 1 ; 56(5):766-71.
PubMed ID: 11068296.
[Link]
605
155 For the budding urologist see: Improving Outcomes in Urological
Cancers. NICE Cancer Service Guideline: Improving Outcomes in Urological
Cancers, downloadable from:
[Link]
606
Urinary tract malignancies
156 Preoperative evaluation of renal anatomy and renal masses with
helical CT, 3D-CT and 3D-CT angiography. Author: Toprak U, Erdo_an A, G"lbay M,
Karademir MA, Pa_ao_lu E, Akar OE. Journal: Diagn Interv Radiol; 2005 Mar ;
11(1):35-40. PubMed ID: 15795842.
[Link]
606
157 Preoperative imaging in renal cell cancer. Author: Heidenreich A,
Ravery V, European Society of Oncological Urology . Journal: World J Urol; 2004
Nov ; 22(5):307-15. PubMed ID: 15290202.
[Link]
606
158 Which is the real gold standard for small-volume renal tumors?
Radical nephrectomy versus nephron-sparing surgery. Author: Manikandan R,
Srinivasan V, Ran" A. Journal: J Endourol; 2004 Feb ; 18(1):39-44. PubMed ID:
15006052.
[Link]
606
159 Interleukin-2- and interferon alfa-2a-based immunochemotherapy in
advanced renal cell carcinoma: a Prospectively Randomized Trial of the German
Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Author: Atzpodien
J et al. Prospectively Randomized Trial of the German Cooperative Renal
Carcinoma Chemoimmunotherapy Group (DGCIN) . Journal: J Clin Oncol; 2004 Apr 1 ;
22(7):1188-94. PubMed ID: 14981107.
[Link]
606
160 Noninvasive detection of clinically occult lymph-node metastases
in prostate cancer. Author: Harisinghani MG, Barentsz J, Hahn PF, Deserno WM,
Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Journal: N Engl J
Med; 2003 Jun 19 ; 348(25):2491-9. PubMed ID: 12815134.
[Link]
606
161 Radical prostatectomy versus watchful waiting in early prostate
cancer. Author: Bill-Axelson A, Holmberg L, Ruutu M, H"ggman M, Andersson SO,
Bratell S, Sp"ngberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO,
Norl"n BJ, Johansson JE, Scandinavian Prostate Cancer Group Study No. 4 .
Journal: N Engl J Med; 2005 May 12 ; 352(19):1977-84. PubMed ID: 15888698.
[Link]
606
162 Androgen suppression adjuvant to definitive radiotherapy in
prostate carcinoma--long-term results of phase III RTOG 85-31. Author: Pilepich
MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO,
Grignon D. Journal: Int J Radiat Oncol Biol Phys; 2005 Apr 1 ; 61(5):1285-90.
PubMed ID: 15817329.
[Link]
606
163 Natural experiment examining impact of aggressive screening and
treatment on prostate cancer mortality in two fixed cohorts from Seattle area
and Connecticut. Author: Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA,
Walker-Corkery ES, Barry MJ. Journal: BMJ; 2002 Oct 5 ; 325(7367):740. PubMed
ID: 12364300.
[Link]
607
164 For the full TNM staging of prostatic carcinoma see:
www.prostateinfo.com/patient/treatment/tnm.asp 607
165 British Journal of
Cancer (2006) 94, 1361-1368. doi:10.1038/sj.bjc.6603105. A model of the natural
history of screen-detected prostate cancer, and the effect of radical treatment
on overall survival. C Parker
[Link]
607
166 British Journal of Cancer (2006) 94, 1361-1368.
doi:10.1038/sj.bjc.6603105. A model of the natural history of screen-detected
prostate cancer, and the effect of radical treatment on overall survival. C
Parker
[Link]
607
